Document Z8O1BEJvG0G1kG3jk7pkKGYZV

Message From: Sent: To: Subject: Beck, Nancy [/0=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=168ECB5184AC44DE95A913297F353745-BECK, NANCY] 1/15/2018 7:17:07 PM Juberg, Daland (DR) [DRJuberg@dow.com] RE: Meeting Items Thanks Daland. OPP staff will be joining me and I'm sure they are looking forward to hearing suggestions. See you Wednesday. Nancy Nancy B. Beck, Ph.D., DABT Deputy Assistant Administrator, OCSPP P: 202-564-1273 M:l Ex" 6 1 L_______________________________ beck.n3ncy@ep3.gov From: Juberg, Daland (DR) [mailto:DRJuberg@dow.com] Sent: Monday, January 15, 2018 11:20 AM To: Beck, Nancy <Beck.Nancy@epa.gov> Subject: Meeting Items Hi Nancy - Thank you again for your willingness to meet with me at 5 PM on Wednesday. Fd like to have a discussion about general advancements, challenges, barriers, oppoitunities that multiple stakeholders might work on tackling - this is not about Dow/Dupont chemistry, but from my vantage point and leaders on some CLA/CLI teams, we are beginning to prioritize where we set topic/issue teams and advanee/utilize science for progression/resolution. I will wel come your inputs on EPA priorities in general or if they get to the point of OPP/HED, that would be helpful as well. There are macro issues/opportunities such as epidemiological data, further w?ork in endocrine, but also science advancement oppoitunities such as replacing defaults with DDEFs, bringing in more toxicokinetic, metabolism data, and exposure-based thinking for testing and risk assessment. If there are key Agency goals/priorities that I can then help move the needle on with my leadership within CLA or thm other venues (SOT, CXI, EPA BOSC), I welcome your thoughts. Thanks in advance. Daland Sierra Club v. EPA 18cv3472 NDCA Tier 3/4 ED 002061 00050129-00001